Orchid Pharma (NSE:ORCHPHARMA) Debt-to-Equity : 0.12 (As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Orchid Pharma Debt-to-Equity?

Orchid Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹144 Mil. Orchid Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹1,208 Mil. Orchid Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹11,695 Mil. Orchid Pharma's debt to equity for the quarter that ended in Mar. 2024 was 0.12.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Orchid Pharma's Debt-to-Equity or its related term are showing as below:

NSE:ORCHPHARMA' s Debt-to-Equity Range Over the Past 10 Years
Min: -136.47 Med: 0.12 Max: 0.74
Current: 0.12

During the past 13 years, the highest Debt-to-Equity Ratio of Orchid Pharma was 0.74. The lowest was -136.47. And the median was 0.12.

NSE:ORCHPHARMA's Debt-to-Equity is ranked better than
68.88% of 842 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs NSE:ORCHPHARMA: 0.12

Orchid Pharma Debt-to-Equity Historical Data

The historical data trend for Orchid Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orchid Pharma Debt-to-Equity Chart

Orchid Pharma Annual Data

Trend

Mar13

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.74

0.69

0.41

0.48

0.12

Orchid Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.48	N/A	0.13	N/A	0.12

Competitive Comparison of Orchid Pharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Orchid Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orchid Pharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orchid Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Orchid Pharma's Debt-to-Equity falls into.

Orchid Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Orchid Pharma's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(143.808	+	1207.998)	/	11694.661
	=	0.12

Orchid Pharma's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(143.808	+	1207.998)	/	11694.661
	=	0.12

Orchid Pharma (NSE:ORCHPHARMA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Orchid Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Orchid Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Orchid Pharma (NSE:ORCHPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orchid Pharma Ltd (NSE:ORCHPHARMA) » Definitions » Debt-to-Equity

Traded in Other Exchanges

524372:India

Address

313, Valluvarkottam High Road, Orchid Towers, Nungambakkum, Chennai, TN, IND, 600 034

Website

http://www.orchidpharma.com

Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment which is Pharmaceutical Products. The company produces various products for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotics, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. The company operates its business throughout the Indian region.

Orchid Pharma (NSE:ORCHPHARMA) Headlines

No Headlines